BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15449444)

  • 1. [Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents].
    Resta L; Sanguedolce F; Orsini G; Laricchia L; Piscitelli D; Fiore MG
    Pathologica; 2004 Apr; 96(2):35-41. PubMed ID: 15449444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
    Kalir T; Goldstein M; Dottino P; Brodman M; Gordon R; Deligdisch L; Wu H; Gil J
    Arch Pathol Lab Med; 1998 May; 122(5):442-6. PubMed ID: 9593346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
    Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
    Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
    Saltiel E
    Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroids (uterine myomatosis, leiomyomas).
    Lethaby A; Vollenhoven B
    Clin Evid; 2004 Dec; (12):2563-85. PubMed ID: 15865807
    [No Abstract]   [Full Text] [Related]  

  • 8. GnRH analogue-induced uterine shrinkage enabling a vaginal hysterectomy and repair in large leiomyomatous uteri.
    Schneider D; Golan A; Bukovsky I; Pansky M; Caspi E
    Obstet Gynecol; 1991 Sep; 78(3 Pt 2):540-1. PubMed ID: 1831252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
    Cohen D; Mazur MT; Jozefczyk MA; Badawy SZ
    J Reprod Med; 1994 May; 39(5):377-80. PubMed ID: 7520497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
    Cramer SF
    Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
    Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
    Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist therapy before myomectomy or hysterectomy.
    Gutmann JN; Corson SL
    J Minim Invasive Gynecol; 2005; 12(6):529-37; quiz 528, 538-9. PubMed ID: 16337584
    [No Abstract]   [Full Text] [Related]  

  • 14. Hormonal therapy before surgical treatment for uterine leiomyomas.
    Moghissi KS
    Surg Gynecol Obstet; 1991 Jun; 172(6):497-502. PubMed ID: 1827931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative efficacy study of the preoperative use of GnRH agonists in women with uterine fibromyomas].
    Nikolov A; Karag'ozov I
    Akush Ginekol (Sofiia); 1999; 38(4):38-42. PubMed ID: 10726353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pulmonary densities following a hysterectomy, caused by benign metastatic leiomyoma].
    Scheer ML; Slebos DJ; Bogchelman DH; Timens W
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2027-31. PubMed ID: 18825892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues.
    Colgan TJ; Pendergast S; LeBlanc M
    Hum Pathol; 1993 Oct; 24(10):1073-7. PubMed ID: 8406417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroids (uterine myomatosis, leiomyomas).
    Lethaby A; Vollenhoven B
    Clin Evid; 2005 Dec; (14):2264-82. PubMed ID: 16620489
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
    Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
    Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of uterine fibroids with GnRH-analogues prior to hysterectomy.
    Stjernquist M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():94-7. PubMed ID: 9225649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.